Focus on cell therapy to treat corneal endothelial diseases

Faye, Pierre-Antoine; Poumeaud, François; Chazelas, Pauline; Duchesne, Mathilde; Rassat, Marion; Miressi, Federica; Lia, Anne‐Sophie; Sturtz, Franck; Robert, Pierre-Yves; Favreau, Fréderic; Benayoun, Y.

doi:10.1016/j.exer.2021.108462

Cited by 25 publications

(34 citation statements)

References 75 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The natural cornea consists of three cellular layers (epithelium, stroma and endothelium) and two acellular layers (Bowman’s and Descemet’s membranes) ( Figure 2 )[ 76 ]. Stroma forms the major part of the cornea, accounting for 90% of the corneal thickness (approximate 500 µm)[ 75 ].…”

Section: Function and Applicationsmentioning

confidence: 99%

Application of Bioprinting in Ophthalmology

Wang¹,

Wang²,

Ji³

et al. 2022

IJB

View full text Add to dashboard Cite

Three-dimensional (3D) bioprinting is an emerging technology that is widely used in regenerative medicine. With the continuous development of the technology, it has attracted great attention and demonstrated promising prospects in ophthalmologic applications. In this paper, we review the three main types of 3D bioprinting technologies: Vat polymerization based bioprinting, extrusion-based bioprinting, and jetting-based bioprinting. We also present in this review the analysis of the usage of both natural and synthesized hydrogels as well as the types of cells adopted for bioinks. Cornea and retina are the two main types of ocular tissues developed in bioprinting, while other device and implants were also developed for the ocular disease treatment. We also summarize the advantages and limitations as well as the future prospects of the current bioprinting technologies based on systematic reviews.

show abstract

Section: Function and Applicationsmentioning

confidence: 99%

Application of Bioprinting in Ophthalmology

Wang¹,

Wang²,

Ji³

et al. 2022

IJB

View full text Add to dashboard Cite

show abstract

“… 102 Another strategy is autologous stem cell-based therapies, which use adult stem cells such as skin-derived precursors, mesenchymal stem cells, and induced pluripotent stem cells for the expansion of corneal endothelial cells. 103 Bioengineered materials have also been developed to aid the expansion of endothelial cells and eventual delivery of cultured cell sheet by intracameral injection. 104 …”

Section: Future Perspectivesmentioning

confidence: 99%

Current Perspectives on Corneal Transplantation (Part 2)

Wong¹,

S²,

Walkden³

2022

OPTH

View full text Add to dashboard Cite

Disease of the cornea is the third leading cause of blindness worldwide. Corneal graft surgery is one of the most successful forms of solid organ transplantations in humans, with ever increasing developments in surgical technique. To date, approximately 4504 corneal transplants are performed in the UK each year. While full thickness transplantation was the most commonly performed keratoplasty over the last few decades, selective lamellar transplantation of the diseased layers of the cornea has been universally adopted. This comprehensive review aims to provide an updated synthesis on different types of corneal transplantations, their treatment outcomes, and the associated complications of each procedure both in adult and pediatric populations. In addition, we also present an up-to-date summary of the emerging therapeutic approaches that have the potential to reduce the demand for donor-dependent keratoplasty.

show abstract

“…The only currently conceivable way to completely dispense with donor material would be to establish suitable protocols for manufacturing clinically applicable pluripotent cells from somatic cells, to establish how to successfully differentiate the cells into the desired (corneal) phenotype and to correct genetic defects (in the case of corneal dystrophies) during these processes [32,33]. Purely pharmacological strategies complement the potential spectrum of corneal regenerative therapies.…”

Section: Cell Therapy and Regenerative Medicinementioning

confidence: 99%

Eye Banks: Future Perspectives

Menzel‐Severing

Salla

Geerling

2021

Klin Monbl Augenheilkd

View full text Add to dashboard Cite

Technological progress and societal change are transforming medicine, and cornea banks are no exception. New infectiological factors, statutory requirements, management concepts, globalisation and digitalisation are also influencing how such facilities will operate in the future. The goal of providing high quality material to patients with corneal disease remains unaltered. The present article seeks to shed light on the type of material this will involve and under what circumstances it is to be obtained.

show abstract

Focus on cell therapy to treat corneal endothelial diseases

Cited by 25 publications

References 75 publications

Application of Bioprinting in Ophthalmology

Application of Bioprinting in Ophthalmology

Current Perspectives on Corneal Transplantation (Part 2)

Eye Banks: Future Perspectives

Contact Info

Product

Resources

About